Deciphering PI3K biology in health and disease

Información del proyecto

Phd

Identificador del acuerdo de subvención: 675392

DOI 10.3030/675392

Proyecto cerrado

Fecha de la firma de la CE 7 Agosto 2015

Fecha de inicio 1 Noviembre 2015

Fecha de finalización 31 Octubre 2019

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total € 3 896 148,12

Aportación de la UE € 3 896 148,12

Coordinado por

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Spain

Resultado final

Other (6)

Research Training Workshop 2

Research Training Workshop

Research Training Workshop 3

Research Training Workshop

Recruitment
Research Training Workshop 4

Research Training Workshop

PhD Completion

Phd Completion

Research Training Workshop 1

Research Training Workshop

Documents, reports (5)

Dissemination and Outreach Plan 1

Dissemination and Outreach Plan

Dissemination and Outreach Plan 2

Dissemination and Outreach Plan

Dissemination and Outreach Plan 3

Dissemination and Outreach Plan

Mid-term review meeting

Meeting with fellows, members of consortium and REA representative to assess the work progress and achievements

Dissemination and Outreach Plan 4

Dissemination and Outreach Plan

Websites, patent fillings, videos etc. (2)

Network Website
Promotional Video

Publicaciones

Peer reviewed articles (5)

Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility

Autores: Ana Angulo-Urarte, Pedro Casado, Sandra D. Castillo, Piotr Kobialka, Maria Paraskevi Kotini, Ana M. Figueiredo, Pau Castel, Vinothini Rajeeve, Maria Milà-Guasch, Jaime Millan, Cora Wiesner, Helena Serra, Laia Muixi, Oriol Casanovas, Francesc Viñals, Markus Affolter, Holger Gerhardt, Stephan Huveneers, Heinz-Georg Belting, Pedro R. Cutillas, Mariona Graupera
Publicado en: Nature Communications, Edición 9/1, 2018, ISSN 2041-1723
Editor: Nature Publishing Group
DOI: 10.1038/s41467-018-07172-3

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Autores: Florent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, Thomas Bohnacker, Anna Melone, Romina Marone, Eileen Jackson, Xuxiao Zhang, Alexander Sele, Chiara Borsari, Jürgen Mestan, Paul Hebeisen, Petra Hillmann, Bernd Giese, Marketa Zvelebil, Doriano Fabbro, Roger L. Williams, Denise Rageot, Matthias P. Wymann
Publicado en: Journal of Medicinal Chemistry, Edición 60/17, 2017, Página(s) 7524-7538, ISSN 0022-2623
Editor: American Chemical Society
DOI: 10.1021/acs.jmedchem.7b00930

The role of metabolic adaptation to nutrient stress in pancreatic cancer

Autores: Abhishek Derle, Maria Chiara De Santis, Luca Gozzelino, Edoardo Ratto, Miriam Martini
Publicado en: Cell Stress, Edición 2/12, 2018, Página(s) 332-339, ISSN 2523-0204
Editor: Shared Science Publishers
DOI: 10.15698/cst2018.12.166

Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics

Autores: Célia Cintas, Thibaut Douché, Nicole Therville, Silvia Arcucci, Fernanda Ramos-Delgado, Céline Basset, Benoît Thibault, Julie Guillermet-Guibert
Publicado en: Cancers, Edición 10/6, 2018, Página(s) 174, ISSN 2072-6694
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers10060174

Experimental pancreatic cancer develops in soft pancreas: novel leads for an individualized diagnosis by ultrafast elasticity imaging

Autores: Nicole Therville, Silvia Arcucci, Aurélie Vertut, Fernanda Ramos-Delgado, Dina Ferreira Da Mota, Marlène Dufresne, Céline Basset, Julie Guillermet-Guibert
Publicado en: Theranostics, Edición 9/22, 2019, Página(s) 6369-6379, ISSN 1838-7640
Editor: Ivyspring International Publisher
DOI: 10.7150/thno.34066